Guilford Pharmaceuticals, Inc.

Baltimore, MD 21014

SBIR Award Summary

Total Number of Awards 9
Total Value of Awards $929K
First Award Date 09/30/97
Most Recent Award Date 06/01/05

Key Personnel

Last Name Name Awards Contact
Slusher Barbara S Slusher 3
Zhang Jie Zhang 2
Hamilton Gregory S Hamilton 2
Rojas Camilo J Rojas 1
Tsukamoto Takashi Tsukamoto 1

9 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/05 - 10/02/05

DESCRIPTION (provided by applicant): The goal of the proposed research is to determine the therapeutic utility of glutaminase inhibitors for the treatment of neurological disorders associated with glutamate excitotoxicity. We will undertake this research using potent and selective small molecule-based inhibitors of glutaminase. Our newly devel...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-02-27
Budget: 04/01/05 - 10/25/05

DESCRIPTION (provided by applicant): The ultimate goal of this work is to commercialize a neuroimmunophilin ligand for cognition enhancement in patients with chronic neurodenerative disease. In preliminary studies in aged rats and primates, neuroimmunophilin ligands have been shown to enhance spatial learning and delayed matching-to-sample perfo...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/08/04 - 08/31/04
PI: Jie Zhang

DESCRIPTION (provided by applicant): The objective for the proposed study is to determine the feasibility of using novel small molecule poly(ADPribose) polymerase (PARP) inhibitors as an adjunct treatment to enhance the antitumor activities of chemotherapeutic agents, especially against metastatic malignancy in brain. Most cancer chemotherapies ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-02-27
Budget: 04/16/04 - 03/31/05

DESCRIPTION (provided by applicant): The ultimate goal of this work is to commercialize a neuroimmunophilin ligand for cognition enhancement in patients with chronic neurodenerative disease. In preliminary studies in aged rats and primates, neuroimmunophilin ligands have been shown to enhance spatial learning and delayed matching-to-sample perfo...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/04 - 09/30/04

A NEW STRATEGY TO DECREASE NMDA RECEPTOR CO-ACTIVATION VIA SERINE RACEMASE INHIBITION - The long goal of this research is to develop and commercialize a serine racemase inhibitor for neurological disease. In phase I we propose to explore the therapeutic utility of serine racemase inhibition in cell culture and animal models of neurological disea...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 02/01/04 - 07/31/04
PI: Jie Zhang

DESCRIPTION (provided by applicant): The objective for the proposed study is to determine the feasibility of using novel small molecule poly (ADP-ribose) polymerase (PARP) inhibitors as neuroprotective and cardioprotective agents to treat cardiac arrest patients for increased survival rate with improving prognosis in neurological and cardiac fun...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/03 - 07/31/04

DESCRIPTION (provided by applicant): We will determine the feasibility of using small molecule inhibitors of Prostate Specific Membrane Antigen (PSMA) conjugated to chemotoxins as targeted prostate cancer (PC) therapy. PC is the most commonly diagnosed malignancy in males in the United States, resulting in 31,000 deaths annually. The dipeptidase...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/97 - 03/31/00

DESCRIPTION: Although cocaine addiction and overdose represent a significant health problem in the United States, there is currently no available pharmacologic treatment. This Phase I proposal is aimed at testing a large number of compounds using a high throughput screening (HTS) technique to find...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/97 - 03/31/00

DESCRIPTION: Although cocaine addiction and overdose represent a significant health problem in the United States, there is currently no available pharmacologic treatment. This Phase I proposal is aimed at testing a large number of compounds using a high throughput screening (HTS) technique to find...